Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience

BACKGROUND: Some patients experience oligo-progression during androgen receptor targeted therapy (ARTT) treatments. This progression might not indicate a real systemic drug resistance, but a selective monoclonal resistance. With the aim to delay the start of new line treatments we treated oligo-prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Valeriani, Maurizio, Marinelli, Luca, Macrini, Serena, Reverberi, Chiara, Aschelter, Anna Maria, De Sanctis, Vitaliana, Marchetti, Paolo, Tronnolone, Lidia, Osti, Mattia Falchetto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857348/
https://www.ncbi.nlm.nih.gov/pubmed/31727093
http://dx.doi.org/10.1186/s13014-019-1414-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857348/
https://www.ncbi.nlm.nih.gov/pubmed/31727093
http://dx.doi.org/10.1186/s13014-019-1414-x

Ejemplares similares